Percutaneous Closure of Ruptured Sinus of Valsalva Aneurysm in a Child Using a Patent Ductus Arteriosus Device.

Ruptured sinus of Valsalva aneurysm is rare, although if left untreated, potentially fatal disease. Surgical approach has been the main treatment in most series; nevertheless, percutaneous closure has been described in selected cases. We report a 5-year-old boy presenting with rapid clinical deterioration who underwent percutaneous closure using a patent ductus arteriosus device, with the resolution of symptoms. Descriptions of this technique being utilized in children are infrequent in the literature.

Giant Right Ventricular Fibroma: Prenatal Diagnosis and Partial Resection in Early Infancy.

Congenital cardiac fibromas are very rare and prenatal diagnosis has been reported in just a few cases. We describe a four-month-old infant presenting a symptomatic giant right ventricular fibroma discovered during prenatal scanning at 33 weeks of gestation, which was confirmed after delivery on echocardiogram and cardiac magnetic resonance imaging. Due to progressive hemodynamic deterioration, partial surgical resection was performed and the patient recovered uneventfully. We report the successful management during early infancy of a giant cardiac fibroma prenatally diagnosed.

Estrategia híbrida en el manejo de cardiopatías congénitas / Hybrid Strategy in the Management of Congenital Heart Defects

RESUMEN Introducción: El abordaje híbrido implica la colaboración estrecha de los equipos quirúrgico y de hemodinamia para el tratamiento de cardiopatías congénitas complejas, con el objetivo de disminuir el número de intervenciones a través de técnicas menos invasivas y de evitar las limitaciones dadas por el tamaño de los accesos vasculares y la utilización de circulación extracorpórea. Objetivos: Evaluar indicaciones, técnicas, resultados iniciales y seguimiento a corto plazo del abordaje híbrido. Material y métodos: Revisión retrospectiva de pacientes abordados de manera híbrida desde marzo de 2014 hasta septiembre de 2020. Se realizaron 14 procedimientos en 13 pacientes. Edad media de 16,8 meses (1 día-13 años), el 50% fueron neonatos y el 57% de sexo masculino; el peso medio fue 9 kg (1,9-70 kg). Los procedimientos híbridos realizados incluyeron implante de stent en coartación de aorta (4 pacientes), implante de stent ductal (3 pacientes), implante de stent ramas pulmonares (1 paciente), valvuloplastia aórtica neonatal (4 pacientes) y cierre de comunicación interventricular muscular (2 pacientes). El acceso se realizó mediante disección carotídea en 8 procedimientos y esternotomía en los 6 restantes. Resultados: Todos los procedimientos pudieron completarse exitosamente, aunque un paciente presentó fibrilación ventricular posprocedimiento y otro falleció durante el posoperatorio inmediato debido a trastorno grave de la coagulación. El seguimiento de los 12 pacientes restantes fue en promedio de 19 meses y la evolución fue favorable. Conclusiones: Utilizando una estrategia híbrida, los resultados iniciales en términos de sobrevida y mejoramiento de parámetros hemodinámicos fueron adecuados. La selección de casos, el trabajo en equipo y el seguimiento apropiado son cruciales para lograr resultados satisfactorios.

ABSTRACT Background: The hybrid approach implies the close collaboration between surgical and interventional cardiology teams for the treatment of complex congenital heart diseases to reduce the number of interventions by using less invasive techniques, avoid the limitations due to the size of vascular accesses and the use of cardiopulmonary bypass. Objectives: The aim of this study is to evaluate the indications, techniques, initial results and short-term follow-up of the hybrid approach. Methods: We conducted a retrospective analysis of patients treated with hybrid approach between March 2014 and September 2020. Fourteen procedures were performed in 13 patients. Mean age was 16.8 years (1 day-13 years); 50% were neonates, 57% were male and mean weight was 9 kg (1.9-70 kg). The hybrid procedures performed included stenting in coarctation of the aorta (4 patients), ductal stenting (3 patients), stenting of pulmonary artery branches (1 patient), neonatal aortic valvuloplasty (4 patients) and perventricular closure of muscular ventricular septal defect (2 patients). The access used was dissection of the carotid artery in 8 procedures and sternotomy in the remaining 6. Results: All the procedures were successfully completed, except for two patients: one died due to ventricular fibrillation after the procedure, and another in the immediate postoperative period due to severe coagulation abnormality. Mean follow-up of the remaining 12 patients was 19 months with favorable outcome. Conclusions: The initial results with the use of a hybrid strategy were satisfactory in terms of survival and improvement of the hemodynamic parameters. The selection of cases, teamwork and appropriate follow-up are key factors to achieve satisfactory results.

Percutaneous closure of the patent ductus arteriosus using the Nit-Occlud PDA-R (reverse) device: initial experience reporting immediate and short-term results.

PURPOSE: To review the initial clinical outcomes of patent ductus arteriosus (PDA) closure using the new Nit-Occlud PDA-R device (NOPDA-R). MATERIALS AND METHODS: The NOPDA-R is a self-expandable, nitinol-made, premounted and cone-shaped device with two distinctive features: reverse reconfiguration of the distal disc and a peculiar "snare-like" release mechanism. From May to December 2010, 20 consecutive patients were included. RESULTS: Median age was 4.7 years (range, 6 months to 21 years) and weight was 16.4 kg (range, 6-49 kg). Mean PDA diameter at its narrowest point, usually the pulmonary end, was 2.92 ± 0.61 mm (range, 2.1-4.5 mm), length was 7.05 ± 1.17 mm (range, 4.7-9.2 mm) and diameter of the aortic ampulla was 9.52 ± 1.62 mm (range, 6-13 mm). Pulmonary artery mean pressure was 20.6 ± 4.49 mmHg (range, 14-28 mmHg) and Qp/Qs ratio was 2.0 ± 0.29 (range, 1.6- 2.5). Implantation success rate was 100%. The median cylinder diameter of the device was 6.53 ± 1.05 mm (range, 5.5-8.5 mm) leading to a final selected device 124% larger (cylinder diameter) than the narrowest PDA diameter. Assessed by transthoracic color-Doppler echocardiography at 24 hours, 1 month, and 3 months after implantation, complete closure was achieved in 60%, 90%, and 95% of patients, respectively. There were no complications and all patients were discharged home the next day. CONCLUSION: Percutaneous PDA closure using the new NOPDA-R device was feasible, safe, and effective. Longer follow-up time and a larger number of patients are required to assess long-term performance.